The story of the European Randomized Study of Screening for Prostate Cancer
2003; Wiley; Volume: 92; Issue: s2 Linguagem: Inglês
10.1111/j.1464-410x.2003.04389.x
ISSN1464-410X
AutoresFritz H. Schröder, L. Denis, Monique J. Roobol,
Tópico(s)Colorectal Cancer Screening and Detection
ResumoBJU InternationalVolume 92, Issue s2 p. 1-13 The story of the European Randomized Study of Screening for Prostate Cancer F.H. Schröder, F.H. Schröder Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands andSearch for more papers by this authorL.J. Denis, L.J. Denis Oncological Centre, Antwerp, BelgiumSearch for more papers by this authorM. Roobol, M. Roobol Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands andSearch for more papers by this authorERSPC, ERSPC Belgium: L.J. Denis, V. Nelen; Finland: A. Auvinen, T. Tammela; France: A. Villers, X. Rebillard; Italy: S. Ciatto, M. Zappa; Spain: A. Berenguer, A. Paez; Sweden: J. Hugosson, P. Lodding; Switzerland: F. Recker, M. Kwiatkowski; The Netherlands: F.H. Schröder, W.J. KirkelsSearch for more papers by this author F.H. Schröder, F.H. Schröder Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands andSearch for more papers by this authorL.J. Denis, L.J. Denis Oncological Centre, Antwerp, BelgiumSearch for more papers by this authorM. Roobol, M. Roobol Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands andSearch for more papers by this authorERSPC, ERSPC Belgium: L.J. Denis, V. Nelen; Finland: A. Auvinen, T. Tammela; France: A. Villers, X. Rebillard; Italy: S. Ciatto, M. Zappa; Spain: A. Berenguer, A. Paez; Sweden: J. Hugosson, P. Lodding; Switzerland: F. Recker, M. Kwiatkowski; The Netherlands: F.H. Schröder, W.J. KirkelsSearch for more papers by this author First published: 13 January 2004 https://doi.org/10.1111/j.1464-410X.2003.04389.xCitations: 96 F.H. Schröder, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Schröder FH. Prostate cancer: to screen or not to screen? BMJ 1993; 306: 407–8 10.1136/bmj.306.6875.407 CASPubMedWeb of Science®Google Scholar 2 Schröder FH, Boyle P. Screening for prostate cancer – necessity or nonsense? Eur J Cancer 1993; 29A: 656–61 10.1016/S0959-8049(05)80339-9 CASPubMedWeb of Science®Google Scholar 3 Bentvelsen FM, Schröder FH. Modalities available for screening for prostate cancer. Eur J Cancer 1993; 29A: 804–11 10.1016/S0959-8049(05)80413-7 CASPubMedWeb of Science®Google Scholar 4 Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61 10.1056/NEJM199104253241702 CASPubMedWeb of Science®Google Scholar 5 Schröder FH, Damhuis RAM, Kirkels WJ et al. European randomized study of screening for prostate cancer – The Rotterdam pilot studies. Int J Cancer 1996; 65: 145–51 10.1002/(SICI)1097-0215(19960117)65:2 3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar 6 Schröder FH, Denis L J, Kirkels WJ, De Koning HJ, Standaert B. European randomized study of screening for prostate cancer: Progress report of Antwerp and Rotterdam pilot studies. Cancer 1995; 76: 129–34 10.1002/1097-0142(19950701)76:1 3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar 7 Auvinen A, Tammela T, Stenman U-H, Uusi-Erkkilä I, Schröder FH, Hakama M. Screening for prostate cancer using serum prostate specific antigen: a randomised, population-based pilot study in Finland. Br J Cancer 1996; 74: 568–72 10.1038/bjc.1996.402 CASPubMedWeb of Science®Google Scholar 8 Auvinen A, Alexander FE, De Koning HJ, Miller AB. Should we start population screening for prostate cancer? Randomised trials are still needed. Int J Cancer 2002; 97: 377–8 10.1002/ijc.1621 PubMedWeb of Science®Google Scholar 9 Recker R, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Retrospective detection of clinically relevant prostate cancer in the prostate-specific antigen range 1–3.0 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166: 851–5 10.1016/S0022-5347(05)65850-8 CASPubMedWeb of Science®Google Scholar 10 Denis L J, Murphy GP, Schröder FH. Report of the consensus workshop on screening and global strategy for prostate cancer. Cancer 1995; 75: 1187–207 10.1002/1097-0142(19950301)75:5 3.0.CO;2-G CASPubMedWeb of Science®Google Scholar 11 Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958–60 10.1016/S0140-6736(94)90071-X CASPubMedWeb of Science®Google Scholar 12 Bartsch G, Horninger W, Klocker H et al. and the Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417–24 10.1016/S0090-4295(01)01264-X CASPubMedWeb of Science®Google Scholar 13 The International Prostate Screening Trial Evaluation Group (IPSTEG). Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999; 35: 262–71 10.1016/S0959-8049(98)00379-7 PubMedWeb of Science®Google Scholar 14 Auvinen A, Rietbergen JBW, Denis L J, Schröder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. J Med Screening 1996; 3: 97–104 10.1177/096914139600300211 CASPubMedGoogle Scholar 15 Koning de HJ, Liem MK, Baan CA, et al. Prostate Cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268–73 10.1002/ijc.10188 CASPubMedWeb of Science®Google Scholar 16 Nijs HTG, Tordoir DMR, Schuurman JH, Kirkels WJ, Schröder FH. Randomised trials of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance. J Med Screening 1997; 4: 102–6 10.1177/096914139700400207 CASPubMedGoogle Scholar 17 Nijs HGT, Essink-Bot ML, De Koning HJ, Kirkels WJ, Schröder FH. Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med 2000; 22: 312–6 10.1093/pubmed/22.3.312 CASPubMedWeb of Science®Google Scholar 18 Ciatto S, Bonardi R, Mazzotta A et al. Comparing two modalities of screening for prostate cancer: digital rectal examination and transrectal ultrasonography vs. prostate specific antigen. Tumori 1995; 81: 225–9 10.1177/030089169508100401 CASPubMedWeb of Science®Google Scholar 19 Ciatto S, Bonardi R, Lombardi C et al. Predicting prostate biopsy outcome by findings at digital rectal examination, Transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population based screening setting. Int J Biol Markers 2001; 16: 179–82 CASPubMedWeb of Science®Google Scholar 20 Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773–8 10.1016/S0090-4295(99)80342-2 CASPubMedWeb of Science®Google Scholar 21 Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 773–8 10.1016/S0090-4295(99)80342-2 CASPubMedWeb of Science®Google Scholar 22 Beemsterboer PMM, Kranse R, De Koning HJ, Habbema JDF, Schröder FH. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer 1999; 84: 437–41 10.1002/(SICI)1097-0215(19990820)84:4 3.0.CO;2-S CASPubMedWeb of Science®Google Scholar 23 Kranse R, Beemsterboer PMM, Rietbergen JBW, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). The Prostate 1999; 39: 316–22 10.1002/(SICI)1097-0045(19990601)39:4 3.0.CO;2-O CASPubMedWeb of Science®Google Scholar 24 Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Pettersson K, Schröder FH. The free-to total prostate-specific antigen ratio improves the specificity of PSA in screening for prostate cancer in the general population. J Urol 1997; 157: 2191–6 10.1016/S0022-5347(01)64712-8 CASPubMedWeb of Science®Google Scholar 25 Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers 2002; 17: 79–83 10.1177/172460080201700201 CASPubMedWeb of Science®Google Scholar 26 Standaert B, Alwan A, Nelen V, Denis L J. Prostate volume and cancer in screening programs. The Prostate 1997; 33: 188–94 10.1002/(SICI)1097-0045(19971101)33:3 3.0.CO;2-F CASPubMedWeb of Science®Google Scholar 27 Rietbergen JWB, Kranse R, Hoedemaeker RF et al. Comparison of PSA corrected for total prostate volume and transition zone volume in a population-based screening study. Urology 1998; 52: 237–46 10.1016/S0090-4295(98)00138-1 CASPubMedWeb of Science®Google Scholar 28 Schröder FH, Van der Maas PJ, Beemsterboer PMM et al. Evaluation of the digital rectal examination (DRE) as a screening test for prostate cancer. JNCI 1998; 90: 1817–23 10.1093/jnci/90.23.1817 CASPubMedWeb of Science®Google Scholar 29 Schröder FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806–12 10.1016/S0022-5347(05)67809-3 CASPubMedWeb of Science®Google Scholar 30 Schröder FH, Roobol-Bouts M, Vis AN, Van Der Kwast TH, Kranse R. PSA based early detection of prostate cancer – Validation of screening without rectal examination. Urology 2001; 57: 83–90 10.1016/S0090-4295(00)00863-3 CASPubMedWeb of Science®Google Scholar 31 Vis AN, Hoedemaeker RF, Van Der Kwast TH, Schröder FH. Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model. The Prostate 2001; 46: 154–62 10.1002/1097-0045(20010201)46:2 3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar 32 Vis AN, Hoedemaeker RF, Roobol M, Kwast van der Th, H, Schröder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0–3.9 ng/ml). The Prostate 2001; 47: 252–61 10.1002/pros.1069 CASPubMedWeb of Science®Google Scholar 33 Aus G, Ahlgren G, Hugosson J, Pedersen KV, Rensfeldt K, Söderberg R. Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination. Scand J Urol Nephrol 1997; 31: 541–4 10.3109/00365599709030659 CASPubMedWeb of Science®Google Scholar 34 Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, Van Der Kwast ThH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000; 56: 617–21 10.1016/S0090-4295(00)00681-6 CASPubMedWeb of Science®Google Scholar 35 Rietbergen JBW, Boeken Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49: 875–80 10.1016/S0090-4295(97)00100-3 CASPubMedWeb of Science®Google Scholar 36 Standaert B, Denis LJ. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997; 80: 1830–4 10.1002/(SICI)1097-0142(19971101)80:9 3.0.CO;2-5 CASPubMedWeb of Science®Google Scholar 37 Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen M, Schröder FH. Complication rates and risk factors of 5802 transrectal ultrasound guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826–30 10.1016/S0090-4295(02)01958-1 PubMedWeb of Science®Google Scholar 38 Finne P, Auvinen A, Aro J et al. Who should be biopsied in prostate cancer screening? Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate Volume and digital rectal examination. Eur Urol 2002; 41: 619–27 10.1016/S0302-2838(02)00179-3 PubMedWeb of Science®Google Scholar 39 Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. Final results of a screening campaign for prostate cancer. Eur Urol 1999; 35: 26–31 10.1159/000019815 CASPubMedWeb of Science®Google Scholar 40 Määttänen L, Auvinen A, Stenman U-H et al. European Randomized Study of Prostate Cancer screening: first-year results of the Finnish trial. Br J Urol 1999; 79: 1210–4 CASPubMedWeb of Science®Google Scholar 41 Ciatto S, Bonardi R, Mazzotta A, Zappa M. Evidence and feasibility of prostate cancer screening. Cancer J 1995; 8: 33–5 Web of Science®Google Scholar 42 Luján M, Paez A, Llanes L, Romero I, Moreno A, Berenguer A. Data of Spanish contribution to the European Randomized Study of Screening for Prostate Cancer (ERSPC). Brazilian J Urol 2000; 26: 510–5 Google Scholar 43 Määttänen L, Auvinen A, Stenman UH et al. Three-year results of the Finnish Prostate Cancer Screening Trial. JNCI 2001; 93: 552–3 10.1093/jnci/93.7.552 CASPubMedWeb of Science®Google Scholar 44 Otto SJ, Van Der Cruijsen IW, Liem MK et al. Effective PSA contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394–9 10.1002/ijc.11074 CASPubMedWeb of Science®Google Scholar 45 Zackrisson B, Aus G, Lilja H, Lodding P, Pihl CG, Hugosson J. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. Eur Urol 2003; 43: 327–32 10.1016/S0302-2838(03)00044-7 PubMedWeb of Science®Google Scholar 46 Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancers in a population-based screening study. J Urol 1999; 161: 1192–8 10.1016/S0022-5347(01)61630-6 CASPubMedWeb of Science®Google Scholar 47 Isola J, Auvinen A, Poutiainen M et al. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001; 165: 1569–74 10.1016/S0022-5347(05)66350-1 CASPubMedWeb of Science®Google Scholar 48 Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50–66 years old with 3–4 ng/ml PSA. J Urol 1998; 159: 899–903 10.1016/S0022-5347(01)63766-2 CASPubMedWeb of Science®Google Scholar 49 Hoedemaeker RF, Rietbergen JBW, Kranse R, Van der Kwast TH, Schröder F. Comparison of pathological characteristics of T1c and non-T1c cancers detected in a population based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 1997; 15: 339–45 10.1007/BF01300181 CASPubMedWeb of Science®Google Scholar 50 Roobol MJ, Kranse R, Van der Cruijsen I, Schröder FH. A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate. Urology 2002; 59: 91–6 10.1016/S0090-4295(01)01479-0 PubMedWeb of Science®Google Scholar 51 Vis AN, Hoedemaeker RF, Roobol M, Schröder FH, Van Der Kwast T. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma. An evaluation from a randomized, population-based study of screening for prostate cancer. Cancer 2001; 92: 524–34 10.1002/1097-0142(20010801)92:3 3.0.CO;2-A CASPubMedWeb of Science®Google Scholar 52 Auvinen A, Määttänen L, Stenman U-H et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279–85 10.1023/A:1015040231402 PubMedWeb of Science®Google Scholar 53 Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study Screening for Prostate Cancer. JNCI 2003; 95: 868–78 10.1093/jnci/95.12.868 PubMedWeb of Science®Google Scholar 54 Hoedemaeker RF, Van Der Kwast TH, Boer R et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. JNCI 2001; 93: 1153–8 10.1093/jnci/93.15.1153 CASPubMedWeb of Science®Google Scholar 55 Van Der Cruijsen-Koeter IW, Van Der Kwast Th, H, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Czancer (ERSPC) – Rotterdam. JNCI 2004; in press Google Scholar 56 Miller AB, Madalinska J. Health-related quality of life and cost-effectiveness studies in the ERSPC and the US PLCO. Eur J Cancer 2001; 37: 2154–60 10.1016/S0959-8049(01)00288-X CASPubMedWeb of Science®Google Scholar 57 Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003; 169: 1720–3 10.1097/01.ju.0000061183.43229.2e CASPubMedWeb of Science®Google Scholar 58 Rietbergen JWB, Boeken Kruger AE, Hoedemaeker RF, Bangma Ch, H, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men. Clinical and pathological features of detected cancers. J Urol 1998; 160: 2121–5 10.1016/S0022-5347(01)62256-0 CASPubMedWeb of Science®Google Scholar 59 Beemsterboer PM, De Koning HJ, Kranse R, Trienekens PH, Van Der Maas PJ, Schroder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J Urol 2000; 164: 1216–20 10.1016/S0022-5347(05)67144-3 CASPubMedWeb of Science®Google Scholar 60 Paez A, Lujan M, Llanes L et al. PSA-use in a Spanish industrial area. Eur Urol 2002; 41: 162–6 10.1016/S0302-2838(01)00022-7 PubMedWeb of Science®Google Scholar 61 Essink-Bot ML, De Koning HJ, Nijs HGT, Kirkels WJ, Van der Maas PJ, Schröder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. JNCI 1998; 12: 925–31 10.1093/jnci/90.12.925 Web of Science®Google Scholar 62 Madalinska JB, Essink-Bot ML, De Koning HJ, Kirkels WJ, Van Der Maas PJ, Schröder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. The Prostate 2001; 46: 87–97 10.1002/1097-0045(20010201)46:2 3.0.CO;2-R CASPubMedWeb of Science®Google Scholar 63 Madalinska JB, Essink-Bot ML, De Koning HJ, Kirkels WJ, Van Der Maas PJ, Schröder FH. Health-related Quality-of-Life effects of radical prostatectomy and primary radiotherapy for screen-detected of clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 1619–28 10.1200/JCO.2001.19.6.1619 CASPubMedWeb of Science®Google Scholar 64 Beemsterboer PMM, De Koning HJ, Birnie E, Van der Maas PJ, Schröder FH. Advanced disease in prostate cancer, course, care and cost implications. The Prostate 1999; 40: 97–104 10.1002/(SICI)1097-0045(19990701)40:2 3.0.CO;2-A CASPubMedWeb of Science®Google Scholar 65 Hakama M, Stenman U-H, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 2189–92 10.1016/S0022-5347(05)65532-2 CASPubMedWeb of Science®Google Scholar Citing Literature Volume92, Issues2December 2003Pages 1-13 ReferencesRelatedInformation
Referência(s)